Equilibrium and stability of neutrino lumps as TOV solutions

We report about stability conditions for static, spherically symmetric objects that share the essential features of mass varying neutrinos in cosmological scenarios. Compact structures of particles with variable mass are held together preponderantly by an attractive force mediated by a background scalar field. Their corresponding conditions for equilibrium and stability are given in terms of the ratio between the total mass-energy and the spherical lump radius, $M/R$. We show that the mass varying mechanism leading to lump formation can modify the cosmological predictions for the cosmological neutrino mass limits. Our study comprises Tolman-Oppenheimer-Volkoff solutions of relativistic objects with non-uniform energy densities. The results leave open some questions concerning stable regular solutions that, to an external observer, very closely reproduce the preliminary conditions to form Schwarzschild black holes.Comment: 20 pages, 5 figure

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Temporal development of the Atherton Basalt Province, North Queensland.

The Atherton Basalt Province is centred on the Atherton Tableland, ∼km southwest of Cairns in north Queensland. Forty-eight K-Ar age determinations and four U/Th analyses from these basalts provide information on the distribution of the volcanics over time. Volcanism commenced at 7.1 Ma and continued into the Early Holocene, with volumetric peaks in activity occurring 3.5-3 Ma and 2-1Ma. The province shows a change with time from eruptions of voluminous lava flows that built relatively large shield volcanoes, to the production of less voluminous lavas and pyroclastics associated with cinder cones during the last million years. Phreatomagmatic, maar-forming eruptions are also preserved among the most recent eruptions. Previous radiocarbon dating of swamp sediments suggested that volcanic activity may have occurred within the past 10 000 years. No systematic change over time is apparent in the location of the volcanoes of the province. Rather, a source region ∼ 80 km in diameter for the province as a whole has evolved over time. Extensive partial melting in the upper mantle may have led to the ascent and adiabatic melting of lesser volumes of mantle material from deeper levels. Changes in lithospheric stresses in north Queensland, caused by the docking of the Ontong Java Plateau and subsequent development of northward subduction at the San Cristobal Trench, may have allowed the ascent of magma from this mantle region

Vector generalized linear and additive extreme value models

10.1007/s10687-007-0032-4Extremes101-21-1